Bulevirtide's Effect Sustained in Difficult-to-Treat Hepatitis D

(MedPage Today) -- Two different dosages of bulevirtide, an investigational first-in-class entry inhibitor, were safe and demonstrated superior responses compared with observation alone for patients with chronic hepatitis delta virus (HDV), a phase...